NCT04781088View on ClinicalTrials.gov

Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 1, 2021

Primary Completion Date

July 1, 2025

Study Completion Date

December 31, 2025

Conditions

Platinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Ovarian CarcinomaPlatinum-Resistant Primary Peritoneal CarcinomaRecurrent Endometrial CarcinomaRecurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal Carcinoma

Interventions

DRUG

Lenvatinib

Given PO

DRUG

Paclitaxel

Given IV

BIOLOGICAL

Pembrolizumab

Given IV

Trial Locations (2)

15224

Allegheny Health Network, Pittsburgh

43210

Ohio State University Comprehensive Cancer Center, Columbus

All Listed Sponsors

lead

Floor Backes, MD

OTHER